Abbreviations
- AE
- adverse event
- ASPIRE
- phase 3 trial of carfilzomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone
- CI
- confidence interval
- CR
- complete response
- EORTC QLQ-C3
- questionnaire developed to assess the quality of life of cancer patients
- HR
- hazard ratio
- HRQoL
- health-related quality of life
- IV
- intravenous
- Dk
- carfilzomib and dexamethasone
- KRd
- carfilzomib, lenalidomide and dexamethasone
- MM
- multiple myeloma
- mPFS
- median progression-free survival
- MR
- minimal response
- ORR
- overall response rate
- PD
- progressive disease
- PFS
- progression-free survival
- PR
- partial response
- QoL
- quality of life
- RESPOND
- phase 3 trial of carfilzomib and dexamethasone vs bortezomib and dexamethasone
- Rd
- lenalidomide and dexamethasone
- sCR
- stem cell transplant
- SD
- stable disease
- SmPC
- Summary of Product Characteristics
- Vd
- bortezomib and dexamethasone
- VGPR
- very good partial response
